Tiziana Life Sciences has filed a patent for a nasal delivery formulation containing foralumab, sodium acetate, polysorbate 80, and sodium chloride. The invention focuses on therapeutic, diagnostic, and prophylactic uses of anti-CD3 antibodies. GlobalData’s report on Tiziana Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Tiziana Life Sciences Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Tiziana Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Tiziana Life Sciences's grant share as of January 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230365689A1) discloses a novel formulation for nasal delivery containing specific concentrations of foralumab, sodium acetate, polysorbate 80, and sodium chloride. The formulation is designed to maintain key characteristics such as being free of microbial contamination, protein aggregates, and retaining lymphocyte proliferation and T-cell activation activity even after storage for three months at 2° C. to 8° C. Additionally, the formulation must have a protein concentration of at least 90% of the starting concentration and a pH of 5.5 ± 0.2 to meet the specified criteria.

Moreover, the patent also describes a unit dose device for intranasal administration of foralumab, ensuring precise delivery of the formulation with a specific droplet size range. The device must deliver a 100 µL dose with a relative standard deviation (RSD) within defined limits. The patent further outlines the acceptable range for foralumab concentration, aggregation levels, pH stability, and potency over an extended storage period. Additionally, a method for treating autoimmune diseases, inflammatory disorders, neurodegenerative diseases, or cancer by administering the disclosed formulation is also included in the patent, with specific mention of multiple sclerosis and Alzheimer's Disease as target conditions for treatment.

To know more about GlobalData’s detailed insights on Tiziana Life Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies